A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
IMVT-1402Placebo is identical to IMP but with no active substance.
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
The proportion of participants remaining Relapse-free by Week 24.
Endpoint detail
Change from baseline to Week 24 in I-RODS., Change from baseline to Week 24 in Mean Grip Strength in the dominant hand., Change from baseline to Week 24 in MRC-SS., Change from baseline to Week 24 in aINCAT score.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.